Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 09/28 10:00:00 pm
169.71 USD   -1.12%
09/28 AMGEN : Announces Erenumab Significantly Reduces Monthly Migraine Da..
09/27 NASDAQ 100 MOVE : Gild, nclh
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
04/27/2012 | 01:22pm CEST

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN, INC.
09/28 AMGEN : Announces Erenumab Significantly Reduces Monthly Migraine Days In Patien..
09/28 AMGEN : Assigned Patent
09/27 NASDAQ 100 MOVERS : Gild, nclh
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/27 AMGEN : Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION ..
09/26 AMGEN : Opens Nomination Process For LabCentral Residency
09/26 AMGEN : And UCB Announce U.S. FDA Acceptance Of Biologics License Application Fo..
09/26 AMGEN : FDA approves lower-cost alternative to biotech drug Humira
09/24 AMGEN : FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of ..
09/24 AMGEN : FDA Approves Amgen's AMJEVITA(TM) (Adalimumab-Atto) For Treatment Of Sev..
More news
Sector news : Bio Therapeutic Drugs
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
09/13DJGILEAD SCIENCES : Scientists Honored for Hep C Research
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/28 Amgen's erenumab (AMG 334) successful in late-stage study in migraine prevent..
09/28 BIOTECH FORUM DAILY DIGEST : Notable Trial Failures; NASH Continues To Be Tough ..
09/27 Amgen's Kyprolis Clarion Call Falls On Deaf Ears
09/27 My 85 Stock Portfolio Evaluation Of Want To Buy Prices And Yields For Purchas..
09/27 Ligand Pharma down 9% on failure of Amgen's Phase 3 Kyprolis study
Financials ($)
Sales 2016 22 769 M
EBIT 2016 11 112 M
Net income 2016 7 441 M
Debt 2016 3 033 M
Yield 2016 2,28%
P/E ratio 2016 17,41
P/E ratio 2017 16,04
EV / Sales 2016 5,77x
EV / Sales 2017 5,33x
Capitalization 128 441 M
More Financials
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 191 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.4.55%129 863
GILEAD SCIENCES, INC.-21.96%106 391
ACTELION LTD19.91%18 591
More Results